Repligen has announced a new licensing agreement with Pfizer in an effort to advance Repligen's spinal muscular atrophy (SMA) program. The work focuses on RG3039, which is a small molecule drug candidate in clinical development for the ...
Tags: Repligen, Pfizer, spinal muscular atrophy, Medicine
Lexicon Pharmaceuticals has won Fast Track status from the US FDA to develop LX1033, an orally-delivered small molecule drug candidate to treat diarrhea-predominant irritable bowel syndrome (IBS-d). Fast Track facilitates the development ...
Tags: Lexicon Pharmaceuticals, small molecule drug candidate